Long-term Follow-up Study of Subjects with Hemophilia B Previously Treated with CSL222

• Research type

  Research Study

• Full title

  An Extension Study Assessing the Long-term Safety and Efficacy of Etranacogene Dezaparvovec (CSL222) Previously Administered to Adult Male Subjects with Hemophilia B

• IRAS ID

  1008420

• Contact name

  Rita Baptista

• Contact email

  cta.gra@cslbehring.com

• Sponsor organisation

  CSL Behring LLC

• Clinicaltrials.gov Identifier

  NCT05962398

• Research summary

  The purpose of this study, CSL222_3003, is to gather information about how safe and how well
  CSL222 works. You will be observed for up to 15 years after you were dosed.

• REC name

  North East - York Research Ethics Committee

• REC reference

  23/NE/0196

• Date of REC Opinion

  24 Nov 2023

• REC opinion

  Further Information Favourable Opinion